• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高浓度生物治疗制剂与超滤:第1部分压力限制

High concentration biotherapeutic formulation and ultrafiltration: Part 1 pressure limits.

作者信息

Lutz Herb, Arias Joshua, Zou Yu

机构信息

Biomanufacturing Sciences Network, EMD Millipore Corporation, 900 Middlesex Turnpike, Billerica, MA, 01821.

Bioprocess R&D, EMD Millipore Corporation, Bedford, MA, 01730.

出版信息

Biotechnol Prog. 2017 Jan;33(1):113-124. doi: 10.1002/btpr.2334. Epub 2016 Oct 15.

DOI:10.1002/btpr.2334
PMID:27452237
Abstract

High therapeutic dosage requirements and the desire for ease of administration drive the trend to subcutaneous administration using delivery systems such as subcutaneous pumps and prefilled syringes. Because of dosage volume limits, prefilled syringe administration requires higher concentration liquid formulations, limited to about 30 cP or roughly 100-300 g L for mAb's. Ultrafiltration (UF) processes are routinely used to formulate biological therapeutics. This article considers pressure constraints on the UF process that may limit its ability to achieve high final product concentrations. A system hardware analysis shows that the ultrafiltration cassette pressure drop is the major factor limiting UF systems. Additional system design recommendations are also provided. The design and performance of a new cassette with a lower feed channel flow resistance is described along with 3D modeling of feed channel pressure drop. The implications of variations in cassette flow channel resistance for scaling up and setting specifications are considered. A recommendation for a maximum pressure specification is provided. A review of viscosity data and theory shows that molecular engineering, temperature, and the use of viscosity modifying excipients including pH adjustment can be used to achieve higher concentrations. The combined use of a low pressure drop cassette with excipients further increased final concentrations by 35%. Guidance is provided on system operation to control hydraulics during final concentration. These recommendations should allow one to design and operate systems to routinely achieve the 30 cP target final viscosity capable of delivery using a pre-filled syringe. © 2016 American Institute of Chemical Engineers Biotechnol. Prog., 33:113-124, 2017.

摘要

高治疗剂量需求以及对给药便利性的追求推动了使用皮下泵和预填充注射器等给药系统进行皮下给药的趋势。由于剂量体积限制,预填充注射器给药需要更高浓度的液体制剂,对于单克隆抗体,其限制在约30厘泊或大致100 - 300克/升。超滤(UF)工艺通常用于配制生物治疗药物。本文考虑了超滤工艺中的压力限制,这些限制可能会限制其达到高最终产品浓度的能力。系统硬件分析表明,超滤盒的压降是限制超滤系统的主要因素。还提供了其他系统设计建议。描述了一种具有较低进料通道流动阻力的新型滤盒的设计和性能,以及进料通道压降的三维建模。考虑了滤盒流动通道阻力变化对放大和设定规格的影响。提供了最大压力规格的建议。对粘度数据和理论的综述表明,分子工程、温度以及使用包括pH调节在内的粘度调节剂可以用于实现更高的浓度。低压降滤盒与辅料的联合使用进一步将最终浓度提高了35%。提供了关于系统操作的指导,以在最终浓缩过程中控制液压。这些建议应能使人们设计和操作系统,以常规实现能够使用预填充注射器给药的30厘泊目标最终粘度。© 2016美国化学工程师学会生物技术进展,33:113 - 124,2017。

相似文献

1
High concentration biotherapeutic formulation and ultrafiltration: Part 1 pressure limits.高浓度生物治疗制剂与超滤:第1部分压力限制
Biotechnol Prog. 2017 Jan;33(1):113-124. doi: 10.1002/btpr.2334. Epub 2016 Oct 15.
2
Ultrafiltration behavior of monoclonal antibodies and Fc-fusion proteins: Effects of physical properties.单克隆抗体和Fc融合蛋白的超滤行为:物理性质的影响
Biotechnol Bioeng. 2017 Sep;114(9):2057-2065. doi: 10.1002/bit.26326. Epub 2017 May 18.
3
Strategies for high-concentration drug substance manufacturing to facilitate subcutaneous administration: A review.高浓度药物物质制造促进皮下给药的策略:综述。
Biotechnol Bioeng. 2020 Nov;117(11):3591-3606. doi: 10.1002/bit.27510. Epub 2020 Aug 3.
4
Filling of High-Concentration Monoclonal Antibody Formulations into Pre-filled Syringes: Investigating Formulation-Nozzle Interactions To Minimize Nozzle Clogging.将高浓度单克隆抗体制剂灌装到预填充注射器中:研究制剂与喷嘴的相互作用以最大限度减少喷嘴堵塞
PDA J Pharm Sci Technol. 2015 May-Jun;69(3):417-26. doi: 10.5731/pdajpst.2015.01055.
5
Multi-criteria manufacturability indices for ranking high-concentration monoclonal antibody formulations.用于对高浓度单克隆抗体制剂进行排名的多标准可制造性指标。
Biotechnol Bioeng. 2017 Sep;114(9):2043-2056. doi: 10.1002/bit.26329. Epub 2017 May 26.
6
A Small-Scale Process for Predicting Donnan and Volume Exclusion Effects During Ultrafiltration/Diafiltration Process Development.超滤/错流过滤过程开发中预测唐南和体积排除效应的小规模方法。
J Pharm Sci. 2018 May;107(5):1296-1303. doi: 10.1016/j.xphs.2018.01.010. Epub 2018 Jan 12.
7
Filling of High-Concentration Monoclonal Antibody Formulations: Investigating Underlying Mechanisms That Affect Precision of Low-Volume Fill by Peristaltic Pump.高浓度单克隆抗体制剂的灌装:探究影响蠕动泵低体积灌装精度的潜在机制。
PDA J Pharm Sci Technol. 2016 Mar-Apr;70(2):143-56. doi: 10.5731/pdajpst.2015.005926. Epub 2016 Jan 21.
8
Ultrafiltration of highly concentrated antibody solutions: Experiments and modeling for the effects of module and buffer conditions.高浓度抗体溶液的超滤:模块和缓冲条件影响的实验与建模
Biotechnol Prog. 2016 May;32(3):692-701. doi: 10.1002/btpr.2252. Epub 2016 May 17.
9
Biopharmaceutical formulations for pre-filled delivery devices.预填充给药装置用生物制药制剂。
Expert Opin Drug Deliv. 2013 Jun;10(6):811-28. doi: 10.1517/17425247.2013.780023. Epub 2013 Mar 19.
10
A Method To Determine the Kinetics of Solute Mixing in Liquid/Liquid Formulation Dual-Chamber Syringes.一种测定液/液剂型双腔注射器中溶质混合动力学的方法。
PDA J Pharm Sci Technol. 2017;71(1):2-10. doi: 10.5731/pdajpst.2016.006601. Epub 2016 Aug 11.

引用本文的文献

1
US FDA-approved therapeutic antibodies with high-concentration formulation: summaries and perspectives.美国食品药品监督管理局批准的高浓度制剂治疗性抗体:概述与展望。
Antib Ther. 2021 Nov 18;4(4):262-272. doi: 10.1093/abt/tbab027. eCollection 2021 Oct.
2
Structure, heterogeneity and developability assessment of therapeutic antibodies.治疗性抗体的结构、异质性和可开发性评估。
MAbs. 2019 Feb/Mar;11(2):239-264. doi: 10.1080/19420862.2018.1553476. Epub 2018 Dec 17.